Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Defence R&D Canada has extended Aradigm's development program for the aerosolized delivery of liposome-encapsulated ciprofloxacin as a treatment for bioterror-related anthrax.
Subscribe to our email newsletter
The extension calls for additional funding of C$662,500 from Defence R&D Canada (DRDC) to execute a preclinical efficacy study of inhaled liposomal ciprofloxacin for post-exposure prophylaxis against inhalational anthrax.
“The extension of this partnership follows significant progress made by Aradigm in formulation and in the execution of a preclinical development program,” said Dr Stephen Farr, chief scientific officer of Aradigm. “The next phase of study with DDRC will focus on efficacy in animal models of inhalation anthrax, the data from which will be key to establishing the regulatory pathway for this product.”
Aradigm is developing the same formulation as used by the DRDC program for its cystic fibrosis liposomal ciprofloxacin program, which is also in the preclinical stage.
The company, with partner Novo Nordisk, is also currently conducting phase III clinical trials of the AERx diabetes management system for the treatment of bothtype 1 and type 2 diabetes.